Kathryn Lindley

Kathie Has Over 20 Years Of Experience In Academia And Industry At UNC-Chapel Hill And GlaxoSmithKline. She Has A Wide Range Of Experience In Cell-Based And Immunoassay Development By Utilizing Platforms, Including ELISA, ELISpot, MSD, DELFIA, RIA, And FMAT.

Kathie is also an expert in the use and interpretation of BIAcore technology due her extensive experience in developing high throughput primary antibody screens using the BIAcore A100. She has developed and holds patents on several monoclonal antibodies that are being progressed as therapeutic agents for sarcopenia, breast cancer, and osteoarthritis.

Since coming to BioAgilytix Labs, Kathie has developed and validated biomarker and immunogenicity assays, both cell-based and plate-based, under GLP regulations. Additionally, her work has been published in peer-reviewed journals, and she has been an invited speaker at national and international meetings. Kathie has a bachelor’s degree from Meredith College and a master’s degree in Microbiology and Immunology from UNC-Chapel Hill.